Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Richard Mazzarella who wrote (25226)	2/5/2000 9:11:00 AM
From: R F B, Jr.	Respond to of 150070

Richard: thanks for the heads up....will look into it over the weekend... rfb

To: Richard Mazzarella who wrote (25226)	2/5/2000 1:15:00 PM
From: myturn	Read Replies (2) \| Respond to of 150070

MDCH, please take the time to read their web site. We have a drug company trading for mere pennies. The majority of them trade at ten times this price. mdch.bizland.com The Company's annual sales volume for its two OTC products developed for herpes simplex virus and acne could possibly exceed 30 million units within 5 years of their introduction and, upon funding, is prepared to launch these products. Management's business experience, in the areas of consumer-products marketing and sales, combined with the efficacy and safety of the products, are expected to transform Meditech from a developmental to an operational company with substantial profitability. Well, they just got their funding last week. "Initial therapeutic uses of MTCH?24? will include the topical treatment of viral and bacterial infections. Dosage forms and uses covered by patents include topical as well as systemic forms. The Marketing Plan has been strategically formulated. Meditech is ready to launch a line of products as financing becomes available. The FDA has issued a series of monographs and proposed monograph regulations concerning certain OTC-drug-product categories and ingredients that have been shown t o be safe and effective for specified uses. Products in such categories containing such ingredients for the specified uses, and which contain additional ingredients for which no new uses are claimed, may under certain conditions be marketed without further FDA approval. Meditech has developed an over-the-counter product containing MTCH?24? for treating the symptoms of herpes simplex virus infections of the lips, mouth, and face (cold sores) and another for the treatment of acne. The Company plans to formulate these and other OTC products to provide treatment for these conditions. Initially, the active ingredients shown in each of the products will be drugs, other than MTCH?24?, that previously have been recognized by the FDA as safe and effective for the intended uses, as specified in FDA monographs or proposed monograph regulations. MTCH-24? will be used in these products as a surfactant. Under these conditions, the Company believes its OTC products will fall within the scope of the FDA regulations and will be able to be brought to market in the United States without further FDA approval. MPI tested a number of drugs to determine their effectiveness against the herpes simplex virus and other micro-organisms. One of those drugs, MTCH?24?, was found to be effective in vitro against herpesviruses. Subsequent testing showed that the drug was effective against a broad range of enveloped viruses as well as selected bacteria and fungi. The active ingredient of MTCH?24? is readily available in over-the-counter products of other companies, but in a different dosage and delivery system, for treatment of disorders unrelated to its use by the Company. The active ingredient of MTCH?24? in those products is not present in sufficient concentrations to render it useful as an anti-microbial agent. Therefore, the Company has formulated topical products containing MTCH?24? in concentrations sufficient to render it effective as an anti-microbial agent. The Company's annual sales volume for its two OTC products developed for herpes simplex virus and acne could possibly exceed 30 million units within 5 years of their introduction and, upon funding, is prepared to launch these products. Management's business experience, in the areas of consumer-products marketing and sales, combined with the efficacy and safety of the products, are expected to transform Meditech from a developmental to an operational company with substantial profitability.